Skip to main content
. 2017 Jul 16;2017:1479137. doi: 10.1155/2017/1479137

Figure 3.

Figure 3

Krox20 gene expression and BDNF production in cells maintained in GGF-2 alone is similar to that of cells in which all stimulating factors have been withdrawn. (a) dASC− had a 4.351 ± 0.552-fold increase in the expression of Krox20 (∗∗∗∗P < 0.0001, n = 3, N = 3); dASC−/+GGF [0.273 nM] cells had a 4.599 ± 0.568-fold increase (∗∗∗∗P < 0.0001, n = 3, N = 3); dASC−/+GGF [2.73 nM] cells a 4.23 ± 0.527-fold increase (∗∗∗∗P < 0.0001, n = 3, N = 3); dASC−/+GGF [5.46 nM] cells a 3.657 ± 0.468-fold increase (∗∗∗P < 0.001, n = 3, N = 3); and dASC−/+GGF [10.92 nM] cells a 3.648 ± 0.148 (∗∗∗P < 0.001, n = 3, N = 3) in Krox20 expression compared to dASC+ cells. There was no significant difference in expression between dASC−/+GGF and dASC−. (b) dASC+ secrete 10 ± 0.440 ng/mL BDNF compared to 4.32 ± 0.184 ng/mL in dASC−, 3.673 ± 0.314 ng/mL in dASC−/+GGF [0.273 nM], 3.695 ± 0.266 ng/mL in dASC−/+GGF [2.73 nM], 4.351 ± 0.257 ng/mL in dASC−/+GGF [5.46 nM], and 4.243 ± 0.208 ng/mL in dASC−/+GGF [10.92 nM] (∗∗∗∗P < 0.0001 for all experimental groups compared to dASC+, n = 3, N = 3).